AEGiS-AIDSWeekly: HIV/AIDS: European Researchers, Regulators, the Pharmaceutical Industry and Activists Demand Better Treatment for People With Hepatitis C and HIV

Important note: Information in this article was accurate in June 2007. The state of the art may have changed since the publication date.

HIV/AIDS: European Researchers, Regulators, the Pharmaceutical Industry and Activists Demand Better Treatment for People With Hepatitis C and HIV

AIDSWEEKLY Plus; Monday, June 4, 2007
Staff Medical Writers

NewsRx -- A unique joint declaration by AIDS activists, doctors, researchers, pharmaceutical companies and members of regulatory agencies has been issued demanding the urgent development of better treatment options for people co-infected with the HIV and hepatitis C (HCV) viruses.

The statement came out of a conference on co-infection that took place in Sitges last month, organised by the European AIDS Treatment Group (EATG).

The Sitges Declaration demands that HIV/HCV co-infected people are included in trials when any new HCV drug is being developed. It calls on government and drug regulatory agencies to develop urgently a set of standards that would expedite drug trials in co-infected people and to develop the best tools for monitoring liver disease.

The statement says: "The patient perspective must be considered part of the HCV drug development process.

"Studies should include people with the most urgent need for new HCV therapies."

Keywords: HIV/AIDS, AIDS, Acquired Immunodeficiency Syndrome, Gastroenterology, HCV, HIV, Hepatitis C Virus, Hepatology, Human Immunodeficiency Virus, Infectious Disease, Pharmaceuticals, Virology, European Aids Treatment Group.

This article was prepared by AIDS Weekly editors from staff and other reports.

2007-06-04
AW070603

Copyright © 2007 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.